A Phase I/II Study of IMMU-132 (hRS7-SN38 AntibodyDrug Conjugate) in Patients with Epithelial Cancer
A study for patients with Epithelial Cancer using study drug IMMU-132
Sponsor: Immunomedics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAP0469
U.S. Govt. ID: NCT01631552
Contact: Jessica Campbell: 212-305-0170 / jc4353@columbia.edu
Additional Study Information: This study is for patients with some form of advanced epithelial cancer and have already received standard therapies for the cancer but has still progressed. The purpose of this study is to test the safety of a new therapy product called IMMU-132 at different dose levels. We want to find out what effects, good and/or bad, it has on patients with advanced epithelial cancer.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Do you have a confirmed diagnosis of epithelial cancer that is Stage IV? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jessica Campbell
jc4353@columbia.edu
212-305-0170
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE